Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Regulators Enforcing More Post-Market Surveillance: Wyeth’s Observations From Enbrel’s Three-year Zenrei Chosa (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

[Editor's note: This is part two of a two-part feature; part one was published in PharmAsia News, Oct. 20, 2008.]

You may also be interested in...



Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?

Chugai Pharmaceutical, the Japanese division of Roche, disclosed that rheumatoid arthritis treatment Actemra (tocilizumab) might have been a causal factor in the death of 15 patients in Japan, reported Japanese media March 18.

Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?

Chugai Pharmaceutical, the Japanese division of Roche, disclosed that rheumatoid arthritis treatment Actemra (tocilizumab) might have been a causal factor in the death of 15 patients in Japan, reported Japanese media March 18.

Japanese Regulators Enforcing More Post-Market Surveillance (Part 1 of 2)

TOKYO - As Japan looks to resolve its drug lag with the West, pharmaceutical companies are finding more and more "all cases surveillance" requirements added as conditions for approval by Japan's Ministry of Health, Labor and Welfare

UsernamePublicRestriction

Register

LL1130496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel